Questcor Pharmaceuticals (QCOR)
Questcor Pharmaceuticals Revenue Growth: 160.5%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
QCOR Revenue Growth Rankings
| Overall | 98th percentile | 80 of 4363 |
| Sector | 94th percentile | 26 of 457 in Healthcare |
| Industry | 83rd percentile | 21 of 126 in Biotechnology |
QCOR Revenue Growth Range, Past 5 Years
| Minimum | -42.76% | Sep 2009 |
| Maximum | 696.5% | Dec 2007 |
| Average | 131.0% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these QCOR related companies
QCOR News
RT @BioDueDiligence $AMRN I'm gonna ask the $arna director who sold under 2 bucks the same question or Don Bailey over at $QCOR why so low
about 5 hours ago by ITradeforMe
about 5 hours ago by ITradeforMe
$MDVN was streetsweeper the same people that hit $QCOR? Nothing became of it.
about 13 hours ago by nomelake
about 13 hours ago by nomelake
$QCOR hearing that borrowing cost is up to 6-7% and climbing. http://stks.co/42UM
about a day ago by s55amg
about a day ago by s55amg
$AAPL small position in common shares, 1 Jul put for insurance, $gld and $QCOR the rest in cash. Don't like markets/Europe. Happy Wkend
about 7 days ago by ssmith98
about 7 days ago by ssmith98
@Momb $QCOR has been on my radar for quite some time, I will however keep an eye on $ALXN and $ARMH... :) thank you....
about 8 days ago by jfrankiep
about 8 days ago by jfrankiep
Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
May 24, 11:58AM PR Newswire
May 24, 11:58AM PR Newswire
Recommends $QCOR via @Markescope Stock Screener
#US #wallstreet #healthcare
about 8 days ago by Momb
about 8 days ago by Momb
$qcor #thestreetsweeper.org shorted another 2,600 shares. What the heck?
about 9 days ago by MarcellusWallace
about 9 days ago by MarcellusWallace
$QCOR - failed this rising trend line. Next support is at $35. http://chart.ly/u3r8n46
about 12 days ago by AffluenzaVirus
about 12 days ago by AffluenzaVirus
$QCOR Concern is always reimbursements long term which is why the PE discount imo
about 13 days ago by ActiveTradingPartners
about 13 days ago by ActiveTradingPartners
Questcor's CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
May 16, 9:46PM Seeking Alpha
May 16, 9:46PM Seeking Alpha
Jefferies Maintains Bullish Stance On Questcor (QCOR) Following Meeting
May 14, 8:28AM Street Insider
May 14, 8:28AM Street Insider
Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 07, 6:30AM PR Newswire
May 07, 6:30AM PR Newswire
UPDATE: Jefferies Raises PT to $52 on Questcor Pharmaceuticals; Solid Q1 Beat
Apr 25, 9:23AM Benzinga
Apr 25, 9:23AM Benzinga
Jefferies Raises Questcor Pharmaceuticals (QCOR) Price Target From $50 to $52
Apr 25, 8:37AM Street Insider
Apr 25, 8:37AM Street Insider
Questcor Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 24, 9:16PM Seeking Alpha
Apr 24, 9:16PM Seeking Alpha
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| QCOR | 41.40 | -0.16 | -0.39% | 2.643B |
| QCOM | 57.31 | -0.14 | -0.24% | 97.17B |
| QCCO | 4.090 | -0.00 | -0.00% | 70.51M |
| QBC | 0.27 | -0.03 | -10.00% | 23.05M |
| QBAK | 1.94 | +0.00 | +0.00% | 23.76M |
| QAI | 27.30 | +0.07 | +0.26% | |
| PW | 8.95 | +0.25 | +2.87% | 14.09M |
| PVTB | 14.73 | -0.08 | -0.54% | 1.073B |
| PVSW | 7.10 | +0.18 | +2.60% | 111.97M |
| PVR | 23.21 | +0.06 | +0.26% | 1.830B |
